

Ingestion of TRP channel agonists attenuates exercise-induced muscle cramps

Daniel H. Craighead¹, Sean W. Shank¹, Jinger S. Gottschall¹ Ph.D., Dennis H. Passe² Ph.D., Bob Murray³ Ph.D., Lacy M. Alexander¹ Ph.D., and W. Larry Kenney¹ Ph.D.

¹ Department of Kinesiology, The Pennsylvania State University, University Park, PA

² Scout Consulting, LLC, Hebron, IL

³ Sports Science Insights, LLC, Crystal lake, IL

Corresponding Author: Daniel H. Craighead
Noll Laboratory, Penn State University
University Park, PA 16802
Phone: (814) 863-8557
Email: dhc139@psu.edu

Running title: TRP agonists attenuate cramps

Acknowledgements: Kyle Volz, Megan Clarke, Ashlee Snyder

Number of words in abstract: 148

Number of words in manuscript: 3812

Ethical Publication Statement: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Conflicts of Interest: Funding and test compounds for this project were provided by Flex Pharma, Inc. (Boston, MA). Sport Science Insights (Bob Murray) serves as an independent consultant to Flex Pharma, Inc. W. Larry Kenney is currently a compensated member of the Scientific Advisory Board of Flex Pharma; however, at the time of the experiments reported herein no financial or other potentially conflicting relationship existed.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/mus.25611

ABSTRACT

Exercise associated muscle cramping (EAMC) is a poorly understood problem that is neuromuscular in origin. Ingestion of transient receptor potential (TRP) channel agonists has been efficacious in attenuating electrically-induced muscle cramps.

PURPOSE: To examine the effect of TRP agonist ingestion on voluntarily-induced EAMC and motor function.

METHODS: Study 1: 39 subjects completed 2 trials after ingesting TRP agonist-containing active treatment (A), or vehicle (V) control. Cramping in the triceps surae muscle was induced via voluntary isometric contraction. Study 2: After ingesting A or V, 31 subjects performed kinematic and psychomotor tests of manual dexterity.

RESULTS: A increased pre-cramp contraction duration (A:36.9±4.1, V:27.8±3.1 s), decreased cramp EMG area under the curve (A:37.3±7.7, V:77.2±17.7 %EMG_{max}•s), increased contraction force to produce the cramp (A:13.8±1.8, V:9.9±1.6 kg), and decreased post-cramp soreness (A:4.1±0.3, V:4.7±0.3 a.u.). Kinematic and psychomotor tests were not affected.

DISCUSSION: TRP agonist ingestion attenuated EAMC characteristics without affecting motor function.

Key Words: exercise associated muscle cramp, α -motor neuron hyperexcitability, TRPV1, TRPA1, EMG

INTRODUCTION

Though exercise associated muscle cramps (EAMC) are common, their etiology is not fully understood. Common theories are that EAMCs are caused by dehydration, altered plasma electrolyte concentrations, or α -motor neuron hyperexcitability¹. Neither hydration nor serum electrolyte status varies between crampers and non-crampers during endurance events^{2,3}. Hypohydration does not change cramp threshold frequency in electrically-induced muscle cramps⁴. These findings suggest that dehydration does not initiate cramping, but does not rule out a role in muscle cramp triggering or susceptibility. Dehydration and electrolyte depletion may increase the rate of muscle fatigue, causing cramping to develop more quickly during exercise¹. Stretching relieves muscle cramps without altering hydration or electrolyte status⁵⁻⁷, demonstrating that restoring electrolyte and fluid balance is not requisite for alleviating EAMC. It has been proposed that a neural mechanism, linked to α -motor neuron hyperexcitability, mediates EAMC and almost certainly comprises the final common pathway.

Transient receptor potential (TRP) channels are involved in sensory transduction of temperature and chemicals^{8,9}. Within the TRP superfamily, activation of different subtypes produces diverse physiological responses. TRP vanilloid 1 (TRPV1) opens in response to high temperature (>42°C) and capsaicin¹⁰, a compound that elicits hot/spicy sensations. TRPV1 is expressed in C and A delta ($\text{A}\delta$)-sensory nerve fibers in most tissues¹⁰. TRP Ankyrin 1 (TRPA1) opens in response to ginger¹¹, and cinnamaldehyde¹¹, which evokes the flavor of cinnamon. TRPA1 is primarily co-located on C and $\text{A}\delta$ -nerve fibers that express TRPV1¹². Both TRPV1 and TRPA1 channels are expressed in the mucosal linings of the mouth, oropharynx, esophagus, and stomach¹³⁻¹⁵, and on spinal nerves^{16,17}.

Strong excitatory sensory stimuli can elicit generalized depression of efferent neural output¹⁸. For example, stimulation of oropharyngeal chemoreceptors with citric acid decreased gastric myoelectrical activity¹⁹. Given the role of TRP channels in sensory transduction, potent TRP channel stimulation has the potential to decrease efferent neural function, including that of α -motor neurons

4 TRP agonists attenuate cramps

innervating skeletal muscle, as demonstrated by Mandadi et al., who showed that treatment of spinal afferents with capsaicin decreased spinal motor nerve output²⁰. Given the widespread expression of TRP channels in the mouth and digestive tract, orally administered TRP channel agonists may decrease excitability of α -motor neurons. This hypothesized mechanism of action is similar to other established pathways where stimulation of the vagus and glossopharyngeal nerves sends afferent signals to the nucleus tractus solitarius, which can subsequently alter efferent motor output²¹.

Given that EAMC is likely neural in nature, stimulation of oral sensory nerves with TRP agonists has the potential to decrease α -motor neuron hyperexcitability and delay or attenuate EAMC. Short et al. showed a 3-fold reduction in electrically-induced muscle cramp intensity in the flexor hallucis brevis after TRP agonist ingestion²² and Rosen et al. found TRP agonists attenuated electrically-induced muscle cramps in the abductor hallucis brevis²³. While electrically-induced cramps are highly reproducible, an exercise-based model of EAMC better reflects real-world conditions.

The goals of the current studies were to (1) assess the effect of oral TRP channel activators on voluntarily-induced muscle cramps, and (2) assess whether potential TRP channel mediated alterations in neural output impair performance of fine psychomotor skills. We hypothesized that activation of oral and upper gastrointestinal TRPV1 and TRPA1 channels would attenuate muscle cramps in a self-induced isometric cramp model, likely by decreasing α -motor neuron hyperexcitability.

MATERIALS AND METHODS

All protocols complied with the Declaration of Helsinki and were approved by the Institutional Review Board at The Pennsylvania State University. Participants provided voluntary written and verbal consent prior to participation in the study.

Study 1: Voluntarily-induced muscle cramps

Subjects

Subjects were young, recreationally active, non-smokers, and free of neuromuscular disease. All subjects reported at least one instance of EAMC during the previous year.

Study Design

This was a double blind, randomized, cross-over study. Subjects visited the lab for three familiarization trials during which they ingested a placebo beverage (flavored water) and underwent a protocol to induce muscle cramping (described below). To be included in the randomized study phase, subjects had to cramp during the first familiarization trial and during one of the subsequent two trials. These initial three trials served to identify subjects with ability to voluntarily reproduce cramps and to minimize learning effects.

Repeat crampers visited the lab on two additional occasions during which they received either the active treatment containing naturally occurring TRP channel activators (A) or a strongly flavored vehicle control (drink base minus the TRP agonists; V) in a randomized, counter-balanced order. All trials, including the familiarization trials, were separated by at least one, but not more than two, weeks.

To ensure blinding of the researchers, drinks were provided in coded bottles. Researchers involved in data analysis left the room while a research assistant delivered the test beverage to prevent researchers from inadvertently smelling the substances or observing involuntary verbal or physical responses from the subjects. Subjects were instructed not to divulge information about the taste profile or other characteristics of the beverages to the researchers. Beverage A had a potent spicy profile while beverage V had a strong fruit taste profile.

Voluntary Cramp Model

Subjects refrained from vigorous exercise for 24 hours, and from consuming food, caffeine, or alcohol for 12 hours prior to each experiment. Subjects were instructed to drink at least six 8-oz glasses of water the day before each experiment.

6 TRP agonists attenuate cramps

Upon arrival, subjects consumed 50 mL of beverage. After finishing the beverage, the lower leg of the subject's choice was prepared for EMG electrode placement. Electromyography (EMG) signals were recorded using a wired amplifier system (iWorx Systems, Inc. IX-BIO8, Dover NH). After skin preparation, 50-mm bipolar, silver-silver chloride, surface electrodes, (SKINTACT, Inverness, FL) were placed over the muscle centers of the medial gastrocnemius, lateral gastrocnemius, tibialis anterior, and soleus with an inter-electrode distance of 2 cm. A single ground was secured to the tibia. After electrode placement, participants were positioned supine on a padded table with a comfortable bend in their hip and knee. The upper leg was supported in the self-selected position with foam padding and the foot was strapped to an adjustable pedal set to the subject's angle of maximal plantar flexion. The pedal was connected to a force transducer to measure force production throughout the study.

Fifteen min after beverage consumption, subjects performed a 5 sec maximum voluntary isometric contraction (MVC) of the triceps surae muscle against the foot pedal to determine maximal force production and for data normalization purposes. Following this 5 sec MVC, subjects elicited EAMC by performing a sustained maximum isometric contraction of the triceps surae against the foot pedal until muscle cramp onset. Immediately upon cramp onset, subjects ceased voluntary contraction and remained motionless until the muscle cramp subsided. If 90 sec of isometric contraction did not produce a cramp, contraction was halted and after 10 min rest the subject again attempted to produce a cramp. This pattern of 90 sec contraction/10 min rest was repeated either until a muscle cramp occurred or the subject was unsuccessful at producing a cramp during 5 attempts.

Immediately after the cramp subsided, subjects rated muscle soreness on a 1 (no soreness) to 10 (extreme soreness) scale. The subject then performed a post-cramp 5-sec MVC to determine maximal force production after cramping. After 20 min rest, a rating of residual soreness was obtained on the same 1 to 10 scale. Joint angles of the subject's lower limb were measured with a goniometer and recorded for identical repositioning on subsequent visits.

Treatments

The active treatment was a proprietary blend of TRPV1 and TRPA1 agonists now marketed as HOTSHOT™ (Flex Pharma. INC.), which included one or more of the following: capsicum (up to 38 mg), cinnamon (up to 500 mg), and ginger (up to 750 mg) dissolved in a fruit flavored base. V comprised the same base solution, free of the TRP channel agonists. Because TRP channel activation is involved in flavor transduction, it is impossible to create a placebo with the same flavor profile as the active treatment. Importantly, both A and V possessed strong, albeit different, flavor profiles. Subjects were not pre-informed about the flavor profiles.

Data Analysis

EMG data were measured on an IX-RA-834 recorder with attached iWire BIO8 and IX-BIO4 biopotential amplifiers (iWorx) and recorded, stored, and analyzed offline using LabScribe3 software (iWorx). Data were sampled at 1000 samples•s⁻¹, bandpass filtered at 100Hz-10kHz, rectified, and integrated with a time constant of 0.001s to calculate area under the curve (AUC) during the pre-cramp isometric contraction and muscle cramp. There was no between-treatment difference in maximum EMG signal (A: 0.59 ± 0.04, V: 0.55 ± 0.04 μV; p=0.39); to account for slight differences in electrode placement between visits altering EMG signal intensity all data were normalized to a percentage of maximum EMG signal (%EMG_{max}; greatest 1% of EMG values during MVC). Cramp onset was noted when subjects first reported a cramp and was confirmed by visual inspection of the EMG signal, identified by quieting of the EMG signal in non-cramping musculature, but continued EMG activity in the cramping musculature²⁴.

Statistics

Results are reported as mean ± standard error (SE). The Student's t-test for related samples (1-tailed) was used to assess differences between A and V. Effect size (ES, Cohen's d), adjusted for correlation, is reported for mean differences. Interpretation of ES follows the convention of Cohen: 0.2,

0.5, 0.8 correspond to ES of “small”, “medium”, and “large”, respectively²⁵. IBM SPSS (version 21) was used for statistical analyses with a 5% level of significance for all statistical tests.

Study 2: Motor Function Study

Subjects

Subjects were young, healthy, recreationally active, non-smokers, free of neurological disease. Subjects in study 2 represented a unique subject sample from study 1 and were not required to have a history of EAMC.

Study Design

Subjects came to the lab on three separate occasions. Participants refrained from vigorous exercise and from consuming caffeine or alcohol for 12 hours. The first visit served as a familiarization trial to orient subjects to the experimental set up and minimize learning effects. Subjects then completed two experimental trials, each 15 min after ingesting either A or V in a randomized, counterbalanced order. Rigorous blinding of subjects and investigators was performed as described for study 1. Experimental trials were separated by at least 24 hours to allow for treatment washout.

Tests

Subjects completed a simulated kinematic reaching task to evaluate upper extremity coordination using an experimental virtual reality based apparatus described previously^{26,27}. Briefly, subjects sat in a chair with arms supported against the effects of gravity and friction by air sleds. Subjects faced an interactive 2D virtual workspace in which stimuli displayed on a 52” HDTV (Sony Electronic Inc.) were reflected onto a mirror that prevented visualization of the arms. The distance between the monitor and the parallel mirror was adjusted to give the illusion that the stimuli appeared in the plane of the fingertips.

A six-degree-of-freedom (6-DOF) Flock of Birds tracking system (Ascension Technology) recorded the position and orientation of the limb segments at 116 Hz sampling rate. 6-DOF sensors were

attached to the middle of each wrist and the middle of each upper arm. The position of the tip of the index finger was recorded relative to the wrist sensor, and positions of the elbow and shoulder joints were recorded relative to the upper arm sensor. The 2D position of the tip of the index finger was used to project the cursor onto the mirror. Data were low-pass filtered using a 12 Hz zero-lag Butterworth filter, prior to differentiating to yield velocity profiles. Outcome measures of interest were maximum velocity, final position error, and deviation from linearity.

Each subject was instructed to adjust display cursor location by moving the cursor from a starting point to a target as quickly and accurately as possible. Each target was individually determined based on subject limb segment length, so all subjects reached for targets that required the same shoulder and elbow angles. Subjects completed 60 trials (30 per arm) then the same protocol was repeated without air sleds and subjects holding their arms up off the table to introduce the effects of gravity.

Subjects then completed a series of standardized psychomotor tests to measure upper limb motor function and manual dexterity. Table 2 (supplementary material available on-line) provides descriptions of the psychomotor tests and outcome measures, as well as descriptions of the three outcome measures of interest for kinematics. All psychomotor tests used are reliable, have been repeatedly validated, and are commonly used in psychomotor research²⁸⁻³¹.

Statistics

Results are reported as mean \pm SE. Student's t-test for related samples (2-tailed) was used to assess differences between treatment and vehicle control conditions. IBM SPSS (version 21) was used for statistical analyses with a 5% level of significance for all statistical tests.

RESULTS

Study 1

10 TRP agonists attenuate cramps

Sixty-four potential subjects with a self-reported history of muscle cramps were initially screened. Nineteen were unsuccessful in producing a muscle cramp on visit 1 and did not participate further. Two others failed to cramp on visits 2 and 3, while 1 failed to cramp during visit 4. Three other participants withdrew from the study due to time constraints, resulting in 39 (15 men, 24 women) participants completing the entire 5-visit protocol. These subjects were young (22 ± 1 y) and had a normal BMI (24 ± 1 kg•m⁻²).

Figure 1 shows a representative original EMG record during isometric muscle contraction and subsequent muscle cramp in two EMG leads.

Results from Study 1 are shown in Figure 2 as both the mean \pm SE and individual responses. There was a significant difference in time to onset of muscle cramping between treatments, with a significantly longer time to cramp onset for A (A: 36.9 ± 4.1 , V: 27.8 ± 3.1 s; $p=0.003$). The effect size for this variable was large (ES=0.70). There was no difference between treatments in the AUC for the EMG signal during pre-cramp contraction (A: 299 ± 48 , V: 277 ± 46 %EMG_{max}•s; $p=0.334$), and the effect size was small (ES=0.10). There was a significant difference between treatments in the average force produced during the muscle contraction prior to cramp onset (A: 13.8 ± 1.8 , V: 9.9 ± 1.6 kg; $p=0.002$), with subjects producing more force before cramping after consuming A (large effect size; ES=0.72).

There was no difference between treatments for the duration that the cramp persisted (A: 14.8 ± 2.2 , V: 16.4 ± 2.2 s; $p=0.144$) and the effect size was small (ES=0.24). The EMG AUC during the muscle cramp showed a significant difference between treatments (A: 37.3 ± 7.2 , V: 77.2 ± 17.7 %EMG_{max}•s; $p=0.010$) with a smaller cramp intensity-duration profile after subjects consumed A (medium effect size; ES=0.63).

There was a significant difference between treatments in the subjective rating of muscle soreness immediately post-cramp (A: 4.1 ± 0.3 , V: 4.7 ± 0.3 a.u.; $p=0.011$), with reported soreness significantly lower after subjects consumed A (medium effect size; ES=0.55). There was no difference in

the ratings of residual muscle soreness 20 minutes post-cramp (A: 2.6 ± 0.2 , V: 2.8 ± 0.3 a.u.; $p=0.092$; data not shown). There was no difference in the MVC force either before cramping (A: 13.5 ± 1.5 , V: 13.2 ± 1.6 kg; $p=0.378$) or after cramping (A: 12.9 ± 1.6 , V: 12.6 ± 1.3 kg; $p=0.299$; data not shown).

Study 2

Thirty-one subjects (12 men, 19 women) were enrolled in and completed the motor function tests. Subjects were young (23 ± 3 y) and had a normal BMI (23 ± 1 kg•m⁻²). Results for study 2 are presented in table 1. There was no treatment effect on any of the kinematic or psychomotor tests.

DISCUSSION

We found that ingesting TRPV1 and TRPA1 channel activators positively improved several cramp-related features in our isometric cramp model, increasing the contraction time and force production prior to cramp initiation, decreasing the EMG time-intensity relation during cramping, and decreasing subjective ratings of muscle soreness immediately after cramp cessation. Conversely, we observed no effect of oral TRP channel activators on fine motor performance. Therefore, we conclude that ingestion of known oral and upper gastrointestinal mucosal TRP channel agonists attenuated the electrical characteristics of voluntary isometric cramps, suggesting benefits in exercise tolerance and performance in those who regularly experience EAMCs, without altering fine motor performance. This suggests that consumption of known TRP agonists would be beneficial for exercise performance in those who regularly experience EAMCs.

With the employed isometric cramp model, our 64% success rate (excluding dropouts) of inducing cramping is similar to previous studies of self-induced muscle cramps^{24,32,33}. We found ingestion of A (relative to V) increased both the static muscle contraction time and force required to produce a cramp; this has relevance for exercise activities as higher intensity or longer duration exercise could be achieved prior to muscle cramp onset. Despite the changes in duration and force, EMG activity

12 TRP agonists attenuate cramps

prior to cramp onset remained the same between treatments, potentially due to the attenuated α -motor neuron hyperexcitability via TRP channel activation.

Cramp duration was not different between A and V; however, the EMG time-intensity relation (i.e., the AUC) during cramping was significantly reduced by A. Though there is expected high inter-individual variability, subjects with the highest EMG AUC with V experienced the greatest reduction in this variable with A. This would suggest a greater efficacy for TRP agonists treating more intense muscle cramps compared to relatively benign cramps. This could be due to a different balance of local and neural factors contributing to the generation of cramps of varying intensities. Finally, post-cramp muscle soreness was reduced with TRP agonist ingestion, likely due to the reduction in muscle cramp intensity producing less residual discomfort.

Our data suggest that TRP channel activation may have dampened α -motor neuron hyperexcitability to mitigate cramping. However, we found that TRP agonist consumption did not affect small motor units (kinematic or psychomotor function) as evidenced by study 2. Since TRP agonists did influence cramping during study 1, it is possible that the TRP agonists target the large motor units. The central nervous system can control force with spatial recruitment or temporal recruitment. Based upon the above results, the agonists influenced spatial recruitment by inhibiting α -motor unit activation to large motor units without a concurrent inhibition of smaller motor units. This is important for exercise and sport as cramping may be attenuated without hampering performance.

These results are very promising for athletes and those who experience muscle cramps during recreational activity. Though the differences between A and V in the variables measured were small, they were significant. All effects we observed suggest that TRP agonist consumption attenuates muscle cramp characteristics as V was never superior to A. In an athletic setting, a small improvement may be enough to incur an advantage over an opponent or achieve a personal best. Overall these results are encouraging and support TRP agonist consumption prior to exercise.

Although increasing evidence points to hyperactive motor neurons as the final mediator of EAMCs, putative triggers that may provoke that hyperactivity are many and varied. Dehydration, hyperthermia, low muscle glycogen, fatigue, muscle damage, and alterations in electrolyte concentration are among the putative triggers for EAMCs. While the present data do not rule out these influences on EAMC, our subjects were presumably euhydrated and in normal electrolyte balance, suggesting that disturbances in these parameters are not requisite for voluntarily-induced cramp generation. Ingesting TRP channel agonists positively altered muscle cramp profiles, supporting the hypothesis that muscle cramps are neuromuscular in origin, regardless of the initiating environment or local milieu. Though TRP channel activation was not measured in this study, TRP channel activation is required for transduction of spicy sensations. Furthermore, Short et al. have empirically demonstrated that a blend of similar TRP agonists opens TRP channels²².

TRPV1 and TRPA1 channels are involved in the transduction of spicy/hot tastes¹⁰ and likely play a role in the mechanism(s) through which muscle cramps were mitigated in this study. It was therefore not possible to formulate a placebo with the same flavor profile as A. Consequently, we used the fluid base and flavoring without the TRP channel agonists for our blinded comparison. The use of a vehicle control beverage ensured that the only difference between trials was the presence or absence of TRP channel agonists. To circumvent the taste difference, subjects were not informed about the active treatment flavor profile. Further, both beverages possessed strong flavor profiles (sweet/fruit and spicy, respectively) leading subjects to assume that either (or both) beverages were designed to treat muscle cramping. Importantly, any placebo effect would necessitate that subjects be able to willfully and selectively control the activation of an isolated area of muscle in the midst of a painful muscle cramp, a highly unlikely scenario.

Limitations

14 TRP agonists attenuate cramps

We did not directly measure TRP channel activation. However, Short et al. tested individual TRP channel agonists derived from biological extracts on *ex vivo* human dorsal root ganglia and found that these TRP channel agonists are capable of opening TRP channels²². Our subjects perceived the spicy flavor, sensory perception that only occurs with TRPV1 and TRPA1 channel activation. It is still possible our findings are non-TRP channel mediated as TRP agonists exert other effects. For example, both TRPV1 and TRPA1 agonists can inhibit voltage-gated sodium channels³⁴⁻³⁶, which could be another avenue through which muscle cramping is attenuated. However, oral consumption of TRP agonists in the amount employed in this study does not significantly increase plasma concentration of these agonists³⁷, supporting the assertion that the effects of TRP agonists are reflex in nature.

Subjects studied were young, healthy, and recreationally active; results cannot be extrapolated to elite athletes or groups with pathology-associated muscle cramps, such as ALS, at this time. However, further research in the ALS population is warranted as those with ALS suffer from muscle cramps derived from motor neuron hyperexcitability³⁸, making TRP agonist consumption a potential therapeutic modality. EAMCs were initiated via isometric muscle contraction. Studies utilizing dynamic exercise models need to be done to confirm that our findings translate to real-world exercise.

Our voluntary cramp model inherently possessed greater variability than electrically-induced models. We sought to decrease within subject variability by having participants complete three familiarization trials. Because this voluntary isometric muscle contraction model was only used in rested, presumably euhydrated subjects, the impact of varying levels of hydration and fatigue are unknown.

Finally, other TRP channel agonists, such as menthol, an agonist for TRP melastatin 8, have the potential to modulate motor unit activity²⁰. It is also not known if oral ingestion of TRP agonists is the most effective means of delivery for attenuating EAMCs. Future research could examine other combinations of TRP agonists and pathways of administration.

Conclusion

In a group of young healthy subjects with a prior cramp history, ingestion of TRP channel agonists 15 min before testing positively altered EAMC characteristics. Conversely, there was no effect of consuming TRP channel activators on any aspect of kinematic or psychomotor measures of motor function mediated by smaller motor units. We conclude that consuming a beverage containing documented TRPV1 and TRPA1 channel activators mitigates self-induced muscle cramps, but does not affect fine motor function.

Accepted Article

Abbreviations**A: active treatment****AUC: area under the curve****EAMC: exercise associated muscle cramps****EMG: electromyography****ES: effect size****LG: lateral gastrocnemius****MG: medial gastrocnemius****MVC: maximum voluntary contraction****SE: standard error****SL: soleus****TA: tibialis anterior****TRP: transient receptor potential****TRPA1: transient receptor potential Ankyrin subtype 1****TRPV1: transient receptor potential vanilloid receptor 1****V: vehicle control**

References

1. Schwellnus MP. Cause of exercise associated muscle cramps (EAMC)--altered neuromuscular control, dehydration or electrolyte depletion? *British journal of sports medicine* 2009;43(6):401-408.
2. Schwellnus MP, Nicol J, Laubscher R, Noakes TD. Serum electrolyte concentrations and hydration status are not associated with exercise associated muscle cramping (EAMC) in distance runners. *British journal of sports medicine* 2004;38(4):488-492.
3. Maughan RJ. Exercise-induced muscle cramp: a prospective biochemical study in marathon runners. *Journal of sports sciences* 1986;4(1):31-34.
4. Miller KC, Mack GW, Knight KL, Hopkins JT, Draper DO, Fields PJ, Hunter I. Three percent hypohydration does not affect threshold frequency of electrically induced cramps. *Medicine and science in sports and exercise* 2010;42(11):2056-2063.
5. Rowland LP. Cramps, spasms and muscle stiffness. *Revue neurologique* 1985;141(4):261-273.
6. Fowler AW. Relief of cramp. *Lancet* 1973;1(7794):99.
7. Daniell HW. Simple cure for nocturnal leg cramps. *The New England journal of medicine* 1979;301(4):216.
8. Clapham DE. TRP channels as cellular sensors. *Nature* 2003;426(6966):517-524.
9. Venkatachalam K, Montell C. TRP channels. *Annual review of biochemistry* 2007;76:387-417.
10. Bevan S, Quallo T, Andersson DA. Trpv1. *Handbook of experimental pharmacology* 2014;222:207-245.
11. Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, Patapoutian A. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. *Neuron* 2004;41(6):849-857.
12. Zygmunt PM, Hogestatt ED. Trpa1. *Handbook of experimental pharmacology* 2014;222:583-630.

18 TRP agonists attenuate cramps

13. Alvarez-Berdugo D, Rofes L, Farre R, Casamitjana JF, Enrique A, Chamizo J, Padron A, Navarro X, Clave P. Localization and expression of TRPV1 and TRPA1 in the human oropharynx and larynx. *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society* 2016;28(1):91-100.
14. Yu X, Yu M, Liu Y, Yu S. TRP channel functions in the gastrointestinal tract. *Seminars in immunopathology* 2016;38(3):385-396.
15. Sobhan U, Sato M, Shinomiya T, Okubo M, Tsumura M, Muramatsu T, Kawaguchi M, Tazaki M, Shibukawa Y. Immunolocalization and distribution of functional temperature-sensitive TRP channels in salivary glands. *Cell and tissue research* 2013;354(2):507-519.
16. Paulsen CE, Armache JP, Gao Y, Cheng Y, Julius D. Structure of the TRPA1 ion channel suggests regulatory mechanisms. *Nature* 2015;520(7548):511-517.
17. Palazzo E, Luongo L, de Novellis V, Berrino L, Rossi F, Maione S. Moving towards supraspinal TRPV1 receptors for chronic pain relief. *Molecular pain* 2010;6:66.
18. Okun M, Lampl I. Instantaneous correlation of excitation and inhibition during ongoing and sensory-evoked activities. *Nature neuroscience* 2008;11(5):535-537.
19. Ashida C, Kojima A, Kobashi M, Koga T. Oro-pharyngeal chemoreceptor activation induces gastric motor response in healthy volunteer subjects. *Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanishi* 2004;40(4-5):211-217.
20. Mandadi S, Nakanishi ST, Takashima Y, Dhaka A, Patapoutian A, McKemy DD, Whelan PJ. Locomotor networks are targets of modulation by sensory transient receptor potential vanilloid 1 and transient receptor potential melastatin 8 channels. *Neuroscience* 2009;162(4):1377-1397.
21. Krahl SE, Clark KB. Vagus nerve stimulation for epilepsy: A review of central mechanisms. *Surgical neurology international* 2012;3(Suppl 4):S255-259.

22. Short G, Hegarty, B., Mackinnon, R., Bean, B., Westphal, C., and Cermak, J. Orally-administered TRPV1 and TRPA1 activators inhibit electrically-induced muscle cramps in normal healthy volunteers. *Neurology* 2015;84(14 Supplement S17.003).
23. Rosen L, Sutherland, R., Solberg, E., Tornblom, A., Hegarty, B., Wessel, T., Westphal, C., and Cermak, J. Synthetic TRP activators demonstrate efficacy in preventing human muscle cramping: potential new drug treatment for muscle cramps and spasticity. *Neurology* 2015;86(16 Supplement P2.275).
24. Khan SI, Burne JA. Reflex inhibition of normal cramp following electrical stimulation of the muscle tendon. *Journal of neurophysiology* 2007;98(3):1102-1107.
25. Cohen J. *Statistical power analysis for the behavioral sciences*. Hillsdale, N.J.: L. Erlbaum Associates; 1988. xxi, 567 p. p.
26. Mutha PK, Stapp LH, Sainburg RL, Haaland KY. Frontal and parietal cortex contributions to action modification. *Cortex; a journal devoted to the study of the nervous system and behavior* 2014;57:38-50.
27. Yadav V, Sainburg RL. Handedness can be explained by a serial hybrid control scheme. *Neuroscience* 2014;278:385-396.
28. Fujisaki W. Effects of delayed visual feedback on grooved pegboard test performance. *Frontiers in psychology* 2012;3:61.
29. Jepsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. *Archives of physical medicine and rehabilitation* 1969;50(6):311-319.
30. Liu CJ, Marie D, Fredrick A, Bertram J, Utley K, Fess EE. Predicting hand function in older adults: evaluations of grip strength, arm curl strength, and manual dexterity. *Aging clinical and experimental research* 2016.
31. Schmitt L. Finger-Tapping Test. In: Volkmar F, editor. *Encyclopedia of Autism Spectrum Disorders*. New York, NY: Springer New York; 2013. p 1296-1296.

20 TRP agonists attenuate cramps

32. Bertolasi L, De Grandis D, Bongiovanni LG, Zanette GP, Gasperini M. The influence of muscular lengthening on cramps. *Annals of neurology* 1993;33(2):176-180.
33. Ross BH, Thomas CK. Human motor unit activity during induced muscle cramp. *Brain : a journal of neurology* 1995;118 (Pt 4):983-993.
34. Cao X, Cao X, Xie H, Yang R, Lei G, Li F, Li A, Liu C, Liu L. Effects of capsaicin on VGSCs in TRPV1-/- mice. *Brain research* 2007;1163:33-43.
35. Matsushita A, Ohtsubo S, Fujita T, Kumamoto E. Inhibition by TRPA1 agonists of compound action potentials in the frog sciatic nerve. *Biochemical and biophysical research communications* 2013;434(1):179-184.
36. Wang SY, Mitchell J, Wang GK. Preferential block of inactivation-deficient Na⁺ currents by capsaicin reveals a non-TRPV1 receptor within the Na⁺ channel. *Pain* 2007;127(1-2):73-83.
37. Short G RL, Sutherland R, Liu J, Cermak JM, Maier G, Wessel T. 537.15 / EEE4 - Chemical Neuro Stimulation of the upper alimentary canal by TRPV1 and TRPA1 activation decreases muscle cramp frequency and severity. *Proceedings of Neuroscience 2016; 2016 November 12-16; San Diego Society of Neuroscience, Washington DC 2016.*
38. Park SB, Kiernan MC, Vucic S. Axonal Excitability in Amyotrophic Lateral Sclerosis : Axonal Excitability in ALS. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics* 2016.

Figure Captions

Figure 1. Representative tracing of EMG signal showing only 2 leads. EMG activity is apparent in both leads during voluntary isometric contraction. When voluntary contraction is halted at cramp onset, EMG activity in lead 1 persists, but lead 2 becomes quite, indicating that cramping is occurring under lead 1. Muscle cramp duration continues until EMG activity in lead 1 becomes quiescent.

Figure 2. Study 1 results. (A) time to cramp onset, i.e., the duration that subjects held isometric contractions before the onset of a muscle cramp. Time to cramp onset was greater when subjects consumed the active treatment (A) compared to the vehicle control (V); (B) EMG intensity-duration area under the curve (AUC) during the pre-cramp isometric muscle contraction (no difference between treatments); (C) mean force produced during pre-cramp isometric contraction. Subjects produced significantly more force when they consumed A compared to V; (D) duration of muscle cramp (no difference between treatments); (E) EMG intensity-duration AUC during EIMC. AUC was significantly smaller when subjects consumed A compared to V; (F) subjective rating of cramp soreness immediately post-cramp. Subjects reported significantly less soreness after consuming A compared to V. * implies treatment difference at $p < 0.05$.

22 TRP agonists attenuate cramps

Table 1. Study 2 results.

Measure	A	V	p-value
Hand Grip Dynamometer (kg)	35.22 ± 1.78	35.01 ± 1.82	0.95
Finger Tapping (taps)	41.98 ± 0.98	41.11 ± 1.31	0.58
JTHFT (s)	103.08 ± 3.18	102.74 ± 3.20	0.86
Pegboard (s)	123.56 ± 2.25	123.08 ± 2.60	0.94
Vmax in 2D (m·s ⁻¹)	0.83 ± 0.01	0.83 ± 0.02	0.89
Final Position Error in 2D (cm)	0.031 ± 0.002	0.031 ± 0.002	0.85
Linearity Deviation in 2D	0.091 ± 0.004	0.090 ± 0.005	0.95
Vmax in 3D (m·s ⁻¹)	0.87 ± 0.019	0.86 ± 0.019	0.76
Final Position Error in 3D (cm)	0.027 ± 0.001	0.027 ± 0.001	0.91
Linearity Deviation in 3D	0.088 ± 0.005	0.090 ± 0.005	0.78

Subjects completed a battery of motor function tests after consuming either the active treatment (A) or vehicle control (V). There was no difference between treatments for any of the tests. (JTHFT: Jebsen-Taylor hand function test). Values are Mean ± SE.




Figure 1. Representative tracing of EMG signal showing only 2 leads. EMG activity is apparent in both leads during voluntary isometric contraction. When voluntary contraction is halted at cramp onset, EMG activity in lead 1 persists, but lead 2 becomes quite, indicating that cramping is occurring under lead 1. Muscle cramp duration continues until EMG activity in lead 1 becomes quiescent.

279x215mm (300 x 300 DPI)

Accep




Figure 2. Study 1 results. (A) time to cramp onset, i.e., the duration that subjects held isometric contractions before the onset of a muscle cramp. Time to cramp onset was greater when subjects consumed the active treatment (A) compared to the vehicle control (V); (B) EMG intensity-duration area under the curve (AUC) during the pre-cramp isometric muscle contraction (no difference between treatments); (C) mean force produced during pre-cramp isometric contraction. Subjects produced significantly more force when they consumed A compared to V; (D) duration of muscle cramp (no difference between treatments); (E) EMG intensity-duration AUC during EIMC. AUC was significantly smaller when subjects consumed A compared to V; (F) subjective rating of cramp soreness immediately post-cramp. Subjects reported significantly less soreness after consuming A compared to V. * implies treatment difference at $p < 0.05$.

279x215mm (300 x 300 DPI)

ACCF